Proposed acquisition will add new anatomic pathology services, proprietary PCR tests and a national client base
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Revenue of $84.1 million, growing 17% year-over-year Raising Full Year 2025 Revenue Guidance to $325.0 million Raising Full Year 2025 EPS Guidance to GAAP loss of approximately...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Core Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of...
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today...
Fulgent Genetics exceeded expectations in the fourth quarter of 2024, showcasing robust revenue growth and a GAAP loss.
Fulgent is moving past its pandemic-era business, and that's a good thing.
Neither has a traditional business model, but that could be an asset for both.